Future of Nicotine Levels in Cigarettes Uncertain
Washington – The Food and Drug Administration may soon have the ability to regulate sales, distribution and advertising of tobacco products, but it would not be allowed to require removal of nicotine from cigarettes.
Nicotine, the most addictive ingredient in a cigarette, increases the level of the dopamine neurotransmitters in the brain.
Dopamine controls many important responses in the brain, such as behavior.
Nicotine spreads in the brain within a few minutes of the first inhalation, creating feelings of reward, which then cause the smoker to continue smoking.
“People may smoke for non-nicotine reasons, but it is the nicotine that is the primary addictive component of cigarettes,” said Dr. Allison Chausmer from the National Institute of Drug Abuse.
Although the FDA would not be able to get rid of nicotine altogether under the bill being considered by Congress, it would have the power to reduce nicotine levels in tobacco products.
The possible benefits for smokers, just like the bill, remain debatable.
A study by the National Institute of Drug Abuse found that tapered reduction of nicotine in cigarettes over a four-week span led one-fourth of smokers who were not trying to quit to spontaneously stop smoking after returning to their regular cigarettes.
“If a cigarette has nicotine levels that are below the level that people find rewarding, it may result in a reduced incidence of smoking initiation and/or increased incidence of quitting,” Chausmer said.
Chausmer also said that if the FDA lowers the nicotine content of cigarettes, “Fewer people will become addicted, and those who are addicted may find it easier to quit.”
However, smokers’ behavior varies, and some, if faced with lower nicotine levels in cigarettes, might smoke more to achieve the same nicotine satisfaction. Chausmer noted that smoking more cigarettes would mean spending more money and taking more time away from work or friends because of today’s smoke-free workplaces and restaurants.
The bill that would give the FDA regulatory power was approved by a House committee last week and will move to the House floor in the coming months.
Source: Farah Khan, Medill Reports, Northwestern University
american lung association, chemical dopamine, cigarette chemicals, dangers of smoking tobacco, fda, national institute of drug abuse, nicotine addiction, nicotine dependency, nicotine in cigarettes, nicotine levels, quit smoking, smoking study, tobacco addiction, tobacco industry, tobacco products, us federal drug administration
What do you think? Please enter your comments below.